Literature DB >> 9605609

Microchimerism and tolerance following intrauterine transplantation and transfusion for alpha-thalassemia-1.

A Hayward1, D Ambruso, F Battaglia, T Donlon, K Eddelman, R Giller, J Hobbins, Y E Hsia, R Quinones, E Shpall, E Trachtenberg, P Giardina.   

Abstract

A fetus homozygous for alpha-thalassemia-1 was given haploidentical paternal CD34 cells at 13, 19 and 24 weeks' gestation and supported through pregnancy by blood transfusion. The fetal hematocrit ranged between 27 and 47% and between one half and three quarters of this hemoglobin was of recipient (Bart's) type. Intrauterine growth proceeded normally and no significant fetal hydrops was detected. Tests for donor HLA antigens, and alpha-globin DNA, were negative on fetal blood samples drawn before birth. A positive signal for alpha-globin DNA was obtained from cord blood and from marrow obtained at 3 months of age, suggesting that some donor stem cells had persisted in the recipient. The infant's blood mononuclear cells showed little proliferative and no cytotoxic response to the donor while responses to a third party were present. Additional paternal CD34 cells given at 3 months age did not reduce transfusion dependency in the subsequent 6 months. Our results show that repeated transfusions can support an alpha-thalassemia-1 fetus through pregnancy, in this instance without significant birth defects or apparent hypoxic tissue injury. The donor stem cells did not have a survival advantage compared with endogenous stem cells, but appeared to survive in the recipient as judged by the persistence of an alpha-globin DNA signal. In vitro studies of alloreactivity suggest tolerization of the host to the donor's MHC disparity. Future efforts will focus on exploiting this tolerance to improve the level of donor chimerism.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9605609     DOI: 10.1159/000020793

Source DB:  PubMed          Journal:  Fetal Diagn Ther        ISSN: 1015-3837            Impact factor:   2.587


  7 in total

1.  Isolation and therapeutic potential of human haemopoietic stem cells.

Authors:  Andrew D Clark; Heather G Jørgensen; Joanne Mountford; Tessa L Holyoake
Journal:  Cytotechnology       Date:  2003-03       Impact factor: 2.058

Review 2.  An international registry of survivors with Hb Bart's hydrops fetalis syndrome.

Authors:  Duantida Songdej; Christian Babbs; Douglas R Higgs
Journal:  Blood       Date:  2017-01-05       Impact factor: 22.113

Review 3.  Fetal Microchimerism in Cancer Protection and Promotion: Current Understanding in Dogs and the Implications for Human Health.

Authors:  Jeffrey N Bryan
Journal:  AAPS J       Date:  2015-02-19       Impact factor: 4.009

Review 4.  Advances in the management of α-thalassemia major: reasons to be optimistic.

Authors:  Paulina Horvei; Tippi MacKenzie; Sandhya Kharbanda
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

5.  In Utero Haematopoietic Stem Cell Transplantation (IUHSCT).

Authors:  Maria Concetta Renda; Aurelio Maggio
Journal:  Mediterr J Hematol Infect Dis       Date:  2009-12-29       Impact factor: 2.576

Review 6.  In utero hematopoietic cell transplantation for hemoglobinopathies.

Authors:  S Christopher Derderian; Cerine Jeanty; Mark C Walters; Elliott Vichinsky; Tippi C MacKenzie
Journal:  Front Pharmacol       Date:  2015-01-12       Impact factor: 5.810

Review 7.  Experimental and clinical progress of in utero hematopoietic cell transplantation therapy for congenital disorders.

Authors:  Chunyu Shi; Lu Pan; Zheng Hu
Journal:  Front Pharmacol       Date:  2022-09-02       Impact factor: 5.988

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.